The findings of study which aimed to evaluate the potential for using resistin as a genetic and biological marker for disease severity and survival in pulmonary arterial hypertension were published on June 6, 2024 in “Pulmonary Research”. Resistin is an adipose-derived hormone (similar to a cytokine). The researchers collected biospecimens, clinical, and genetic data for 1.121 adults with pulmonary arterial hypertension, including 808 with idiopathic pulmonary arterial hypertension and 313 with scleroderma-associated pulmonary arterial hypertension from a national repository.
Resistin levels were found to be significantly higher in all pulmonary arterial hypertension samples and pulmonary arterial hypertension subtype (idiopathic and scleroderma-related) samples than in the control group, and had significant discriminative abilities. High resistin levels were associated with older age, shorter 6-min walk distance, and reduced cardiac performance.
The researchers conclude that resistin represents a novel biomarker for pulmonary arterial hypertension prognostication and may indicate a new therapeutic avenue.
Read more at this link on the Respiratory Medicine website.
Citation
Gao, L., Skinner, J., Nath, T. et al. Resistin predicts disease severity and survival in patients with pulmonary arterial hypertension. Respir Res 25, 235 (2024). https://doi.org/10.1186/s12931-024-02861-8
